Clinical Trials Logo
  1. Home
  2. Radiation Toxicity
  3. NCT03139318
  4. Details
NCT03139318 Clinical Trial

Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity

Radiation Toxicity Clinical Trial

Official title:
Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT03139318
Other study ID # 205993
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date July 25, 2017
Est. completion date August 29, 2018

Study information
Verified date June 2022
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the toxicity profile of GRID therapy using dose levels of 10Gy, 15 Gy and 20Gy in pediatric osteosarcoma of the extremity.

Description:

Subjects will receive GRID radiotherapy. GRID radiation therapy is considered a standard radiation therapy method however is not typically used in pediatric osteosarcoma patients. This protocol will evaluate whether or not the use of this therapy will provide benefit to this patient population.

Recruitment information / eligibility
Status Terminated
Enrollment 1
Est. completion date August 29, 2018
Est. primary completion date August 29, 2018
Accepts healthy volunteers No
Gender All
Age group 5 Years to 21 Years
Eligibility Inclusion Criteria: - History of cytological or histological documentation of non-metastatic extremity osteosarcoma. - 5-21 years of age. - Subject is eligible for routine chemotherapy and routine surgery for the treatment of non-metastatic extremity osteosarcoma - Informed consent is obtained Exclusion Criteria: - Females with a positive urine pregnancy test. - Unable to comply with study procedures

Study Design

Related Conditions & MeSH terms

Intervention

Radiation:
• GRID radiotherapy
Patients will be treated with GRID radiotherapy

Locations
Country Name City State
United States University of Arkansas for Medical Sciences Little Rock Arkansas

Sponsors (1)
Lead Sponsor Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Participants With Toxicities Associated With GRID Radiotherapy The study endpoint is dose-limiting toxicity (DLT), which is defined as a treatment-related AE of Grade 3 or higher. An average of 12 months
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT02058550 - Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Phase 1
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT01407770 - Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Completed NCT00003313 - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase 3
Completed NCT03783364 - Pre- or Postoperative Accelerated Radiotherapy N/A
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Recruiting NCT04110223 - Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Active, not recruiting NCT02259218 - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Completed NCT01170299 - Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer N/A
Completed NCT00974168 - Spinal Cord Compression Re-Treat Study Phase 2
Completed NCT00008398 - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury